RTTNews BiotechDoubao · 实盘不做把握 6/10不做原因:已被定价
北京时间·🕒 发布 19:28:18·⟳ 抓取 19:30:23 +2m05s·⚡ 决策 09-14 20:30:26 +1h00m·42.7 天前
BioNTech公布gotistobart肺鳞癌III期Stage 1更新：中位总生存18.5对10.0个月近乎翻倍，盘前一度涨约8%
这是真实且临床意义较强的OS更新，但：①核心OS获益方向2025-12-05已由公司公告、Stage 1已登Nature Medicine，本次为更长随访的更新而非新的注册性阳性读出（pivotal Stage 2仍在进行，p=0.0295为名义值、n=87）；②消息在盘前已被重定价约6%、高点+7.9%后回落；③对243亿美元市值的BioNTech而言单一资产中短期无收入贡献，且近期有指引下调/亏损扩大/管理层更替等逆风；④合作方OncoC4私有、无A/H映射标的。做多edge不足，数据正面又不支持做空，故双向回避。
📄 原文RTTNews Biotech↗ 原文
BioNTech's Gotistobart Nearly Doubles Median Overall Survival In Previously Treated Squamous NSCLC
Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…
不做 BioNTech SE（BNTX.US）
OS数据真实正面但属2025-12已披露获益的会议随访更新，pivotal Stage 2未读出；盘前已涨约6%并从+7.9%回落，243亿美元市值短期弹性有限且近期有亏损扩大/指引下调/CEO更替逆风，追多风险收益不足；数据正面不构成做空催化，双向不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
gotistobart在经治肺鳞癌中近乎翻倍中位OS（18.5 vs 10.0个月），数据正面但属去年12月已披露OS获益的随访更新，pivotal Stage 2未读出；BNTX盘前已涨约6%、超大市值且近期基本面有逆风，追多风险收益差，OncoC4私有无映射标的，故不做。
消息传播链
- 公司已于2025年12月公告gotistobart在经治鳞状NSCLC中具临床意义的OS获益，确立方向
- gotistobart获FDA鳞状NSCLC孤儿药资格认定
- WCLC更新随访：中位OS 18.5 vs 10.0个月，HR 0.56，名义p=0.0295
- RTTNews报道时BNTX盘前报101.60美元、涨5.03%
- 2026-09-14 08:25 ET市场反应futu盘前行情盘前约102.53美元（+6.0%），盘前区间98.78–104.40（高点+7.9%）后回落，量约3.3万股，显示资金已在实时重定价且追高动能减弱市场反应:BNTX盘前+6%，较高点回落
关键理由
- OS 18.5 vs 10.0个月、HR 0.56且安全性更优，支持gotistobart差异化机制，但该方向去年12月已公开，属增量成熟度更新而非新催化
- 对243亿美元市值、拥有20多个II/III期管线的BioNTech，单一未申报资产的Stage 1更新难形成重大短期业绩弹性
主要风险
- 名义p=0.0295、样本仅87例且为开放标签Stage 1，pivotal Stage 2的OS主要终点尚未读出，存在复现风险
- 盘前已涨约6%并从+7.9%回落，叠加两天后FOMC，事件驱动资金可能高开低走
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08 · 影响 weakens
RTTNews相关链接显示BioNTech Q2净亏损扩大、下调FY26收入展望、任命新CEO、终止autogene cevumeran结直肠癌II期试验，构成近期基本面逆风
检索:BioNTech Q2 loss widens lowers FY26 revenue outlook CEO change colorectal trial terminate 原文 ↗ - 做多前查反向 · 来源 web · 日期 2025-12-05 · 影响 weakens
OS获益方向已在2025年12月官方披露并被Nature Medicine发表，今日为更新随访，新增信息量有限
检索:gotistobart PRESERVE-003 overall survival already announced December 2025 原文 ↗
先例如何影响了这次决策
对本次决策的影响:支持在PRICE_IN/RISK_REWARD下回避追多，未据此产生任何交易腿
方向:未构建对齐先例面板：结论为AVOID，且核心理由是旧闻更新+盘前已price-in+超大市值弹性不足，先例幅度不会改变不做结论
涨幅量级:不足：本次为Stage 1更新、pivotal未读出，与典型III期topline阳性/获批事件相位不同，强行套用会高估涨幅
形态:盘前+6%且从+7.9%回落，符合'会议更新数据高开后部分兑现'的观察，但无干净同市场首发先例样本支撑统计结论
工具执行结果 · 成功 8 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 16 ms
{"result": "search_processed_events:agent query=`biontech gotistobart bnt316 onc-392 preserve-003 squamous nsclc overall survival | oncoc4 gotistobart phase 3 lung cancer data 18.5 months`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正 - fetch_decision_experience 成功 stock_tools HTTP · 86 ms
{ - web_search 成功 doubao_search · 1,974 ms
豆包搜索结果（原始查询:OncoC4 go public merger SPAC ticker gotistobart；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 628 ms
{ - web_search 成功 doubao_search · 2,424 ms
豆包搜索结果（原始查询:AcroImmune public company ticker NASDAQ OncoC4 merger close；API SearchType:web） - web_search 成功 doubao_search · 2,230 ms
豆包搜索结果（原始查询:gotistobart PRESERVE-003 overall survival December 2025 BioNTech interim data squamous NSCLC HR；API SearchType:web） - web_search 成功 doubao_search · 1,911 ms
豆包搜索结果（原始查询:BioNTech gotistobart December 2025 press release median overall survival hazard ratio squamous NSCLC "Stage 1" number months；API SearchType:web） - web_search 成功 doubao_search · 2,099 ms
豆包搜索结果（原始查询:ONC-397 gotistobart 昂科免疫 中国 权益 上市 BioNTech 大中华区；API SearchType:web）
原文全文
展开原文 · 9,312 字
BioNTech's Gotistobart Nearly Doubles Median Overall Survival In Previously Treated Squamous NSCLC
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
BioNTech's Gotistobart Nearly Doubles Median Overall Survival In Previously Treated Squamous NSCLC
By
RTTNews Staff Writer
✉
Published:
9/14/2026 7:28 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
BioNTech SE (
BNTX
) and OncoC4, Inc. announced updated data from Stage 1 of the PRESERVE-003 Phase 3 trial showing that gotistobart (BNT316/ONC-392) nearly doubled median overall survival compared with standard-of-care chemotherapy in patients with previously treated squamous non-small cell lung cancer (NSCLC).
At the July 17, 2026 data cutoff, 87 patients with metastatic squamous NSCLC who had progressed on prior immunotherapy and chemotherapy were randomized to gotistobart monotherapy or docetaxel.
After a median follow-up of 25.4 months, median overall survival was 18.5 months with gotistobart versus 10.0 months with docetaxel, representing a 44% reduction in the risk of death (HR 0.56; nominal p=0.0295).
Gotistobart demonstrated a manageable safety profile consistent with previously reported data. Grade 3 or higher treatment-related adverse events occurred in 44.4% of patients receiving gotistobart compared with 48.8% of those receiving docetaxel.
Rama Balaraman, M.D., Principal Investigator and medical oncologist at Ocala Oncology Center, said the magnitude of the survival benefit observed with gotistobart was encouraging and could potentially transform treatment in a setting where patients have limited options.
Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech, said the findings highlight gotistobart's differentiated mechanism and potential to re-engage suppressed or exhausted antitumor immune responses in previously treated lung cancer.
About the PRESERVE-003 Phase 3 Trial
PRESERVE-003 is a two-stage, open-label Phase 3 trial evaluating gotistobart monotherapy against docetaxel in patients with squamous NSCLC whose disease has progressed following PD-(L)1 inhibitors and platinum-based chemotherapy.
The ongoing pivotal Stage 2 portion is being conducted at more than 160 sites globally, with overall survival as the primary endpoint and objective response rate, progression-free survival and safety as secondary endpoints.
BNTX has traded between $79.52 and $124.0 over the past year. The stock closed Friday's trading (September 11, 2026) at $96.73, up 0.34%. In pre-market trading the stock is at $101.60, up 5.03%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Biotech Stocks Facing FDA Decision In July 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher Amid Inflation Data Release, Expectations Of Reopening Of Strait Of Hormuz
September 11, 2026 17:00 ET
Crude Oil Slumps Amid Rising Expectations Of An End To Hormuz Crisis, Profit-taking
September 11, 2026 14:41 ET
U.S. Dollar Advances Amid Oil-Linked Inflation Concerns, PPI Data Release
September 10, 2026 17:00 ET
U.S. Stocks Show Significant Rebound As Crude Oil Pulls Back Sharply
September 11, 2026 16:13 ET
Canadian Stocks Tumble Amid Increasing Concerns Of Oil-linked Inflation, Canada-U.S. Tariff War
September 10, 2026 16:32 ET
View More
Global Economics Weekly Update - Sep 07 – Sep 11, 2026
September 11, 2026 16:26 ET
Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.
View More Videos
RELATED NEWS
BioNTech's Gotistobart Nearly Doubles Median Overall Survival In Previously Treated Squamous NSCLC
BioNTech Terminates Phase 2 Trial Of Autogene Cevumeran In Colorectal Cancer
BioNTech SE Q2 Loss Rises
BioNTech Q2 Net Loss Widens, Lowers FY26 Revenue Outlook; Stock Falls In Pre-Market
BioNTech Appoints Oelkers As CEO, Succeeding Co-Founder Sahin
Latest Updates on COVID-19
COVID-19 Sees Late-Summer Rise Across 49 US States
September 03, 2026 12:52 ET
COVID-19 Infections Rising In All 50 US States, CDC Data Shows
August 20, 2026 14:09 ET
COVID-19 Pandemic Linked To Higher Loneliness And Isolation In England, Study Finds
August 19, 2026 14:02 ET
View More
Editor's Pick
Most Read
Most Emailed
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Google To Invest 13 Bln Euros In Finland To Develop AI Infra, Clean Energy
September 09, 2026 09:11 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Orion180 Plans Up To $340 Mln IPO
September 09, 2026 08:04 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
HP Partners With Red Hat For AI Workloads; Shares Up
September 09, 2026 15:46 ET
Apple Unveils New AirPods And Apple Watch Lineup With Enhanced Audio, Health And AI Features
September 09, 2026 16:47 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Blackstone To Buy Flow Control Holdings From Audax For Undisclosed Terms
September 10, 2026 11:20 ET
Atlantic HPC Group To Go Public Via Aperture AC Merger
September 11, 2026 08:16 ET
SEALSQ H1 Loss Widens From Higher Expenses; Reaffirms FY26 Outlook
September 11, 2026 13:24 ET
Ageas Completes Sale Of 30.95% Maybank Ageas Stake To Maybank For EUR 1.1 Bln
September 11, 2026 01:43 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
E79 Gold Mines Limited Full Year Sales Increase
September 09, 2026 01:00 ET
Holcim Invests In Cloud Cycle
September 09, 2026 03:16 ET
Everpure To Join S&P 500
September 09, 2026 01:09 ET
ASE Technology August Revenues Rise 34.6% Y-o-Y
September 09, 2026 03:18 ET
Scientex Berhad Q4 Income Climbs
September 09, 2026 01:12 ET
Victrex Plc Raises FY26 Underlying PBT View; Appoints Interim CFO; Stock Rises 12.8%
September 09, 2026 03:28 ET
Chime To Acquire Stride Bank
September 09, 2026 01:26 ET
Autohellas S.A. Reveals Fall In H1 Profit
September 09, 2026 03:33 ET
Antin Infrastructure Partners SAS Profit Drops In H1
September 09, 2026 01:29 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Vallourec, Aramco Ink Agreement For Supply Of Oil Country Tubular Goods
September 09, 2026 01:45 ET
TENPOS HOLDINGS Co Ltd. Reveals Retreat In Q1 Profit
September 09, 2026 05:03 ET
Editors Pick
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Loading...
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
BioNTech's Gotistobart Nearly Doubles Median Overall Survival In Previously Treated Squamous NSCLC
By
RTTNews Staff Writer
✉
Published:
9/14/2026 7:28 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
BioNTech SE (
BNTX
) and OncoC4, Inc. announced updated data from Stage 1 of the PRESERVE-003 Phase 3 trial showing that gotistobart (BNT316/ONC-392) nearly doubled median overall survival compared with standard-of-care chemotherapy in patients with previously treated squamous non-small cell lung cancer (NSCLC).
At the July 17, 2026 data cutoff, 87 patients with metastatic squamous NSCLC who had progressed on prior immunotherapy and chemotherapy were randomized to gotistobart monotherapy or docetaxel.
After a median follow-up of 25.4 months, median overall survival was 18.5 months with gotistobart versus 10.0 months with docetaxel, representing a 44% reduction in the risk of death (HR 0.56; nominal p=0.0295).
Gotistobart demonstrated a manageable safety profile consistent with previously reported data. Grade 3 or higher treatment-related adverse events occurred in 44.4% of patients receiving gotistobart compared with 48.8% of those receiving docetaxel.
Rama Balaraman, M.D., Principal Investigator and medical oncologist at Ocala Oncology Center, said the magnitude of the survival benefit observed with gotistobart was encouraging and could potentially transform treatment in a setting where patients have limited options.
Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech, said the findings highlight gotistobart's differentiated mechanism and potential to re-engage suppressed or exhausted antitumor immune responses in previously treated lung cancer.
About the PRESERVE-003 Phase 3 Trial
PRESERVE-003 is a two-stage, open-label Phase 3 trial evaluating gotistobart monotherapy against docetaxel in patients with squamous NSCLC whose disease has progressed following PD-(L)1 inhibitors and platinum-based chemotherapy.
The ongoing pivotal Stage 2 portion is being conducted at more than 160 sites globally, with overall survival as the primary endpoint and objective response rate, progression-free survival and safety as secondary endpoints.
BNTX has traded between $79.52 and $124.0 over the past year. The stock closed Friday's trading (September 11, 2026) at $96.73, up 0.34%. In pre-market trading the stock is at $101.60, up 5.03%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Biotech Stocks Facing FDA Decision In July 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher Amid Inflation Data Release, Expectations Of Reopening Of Strait Of Hormuz
September 11, 2026 17:00 ET
Crude Oil Slumps Amid Rising Expectations Of An End To Hormuz Crisis, Profit-taking
September 11, 2026 14:41 ET
U.S. Dollar Advances Amid Oil-Linked Inflation Concerns, PPI Data Release
September 10, 2026 17:00 ET
U.S. Stocks Show Significant Rebound As Crude Oil Pulls Back Sharply
September 11, 2026 16:13 ET
Canadian Stocks Tumble Amid Increasing Concerns Of Oil-linked Inflation, Canada-U.S. Tariff War
September 10, 2026 16:32 ET
View More
Global Economics Weekly Update - Sep 07 – Sep 11, 2026
September 11, 2026 16:26 ET
Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.
View More Videos
RELATED NEWS
BioNTech's Gotistobart Nearly Doubles Median Overall Survival In Previously Treated Squamous NSCLC
BioNTech Terminates Phase 2 Trial Of Autogene Cevumeran In Colorectal Cancer
BioNTech SE Q2 Loss Rises
BioNTech Q2 Net Loss Widens, Lowers FY26 Revenue Outlook; Stock Falls In Pre-Market
BioNTech Appoints Oelkers As CEO, Succeeding Co-Founder Sahin
Latest Updates on COVID-19
COVID-19 Sees Late-Summer Rise Across 49 US States
September 03, 2026 12:52 ET
COVID-19 Infections Rising In All 50 US States, CDC Data Shows
August 20, 2026 14:09 ET
COVID-19 Pandemic Linked To Higher Loneliness And Isolation In England, Study Finds
August 19, 2026 14:02 ET
View More
Editor's Pick
Most Read
Most Emailed
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Google To Invest 13 Bln Euros In Finland To Develop AI Infra, Clean Energy
September 09, 2026 09:11 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Orion180 Plans Up To $340 Mln IPO
September 09, 2026 08:04 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
HP Partners With Red Hat For AI Workloads; Shares Up
September 09, 2026 15:46 ET
Apple Unveils New AirPods And Apple Watch Lineup With Enhanced Audio, Health And AI Features
September 09, 2026 16:47 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Blackstone To Buy Flow Control Holdings From Audax For Undisclosed Terms
September 10, 2026 11:20 ET
Atlantic HPC Group To Go Public Via Aperture AC Merger
September 11, 2026 08:16 ET
SEALSQ H1 Loss Widens From Higher Expenses; Reaffirms FY26 Outlook
September 11, 2026 13:24 ET
Ageas Completes Sale Of 30.95% Maybank Ageas Stake To Maybank For EUR 1.1 Bln
September 11, 2026 01:43 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
E79 Gold Mines Limited Full Year Sales Increase
September 09, 2026 01:00 ET
Holcim Invests In Cloud Cycle
September 09, 2026 03:16 ET
Everpure To Join S&P 500
September 09, 2026 01:09 ET
ASE Technology August Revenues Rise 34.6% Y-o-Y
September 09, 2026 03:18 ET
Scientex Berhad Q4 Income Climbs
September 09, 2026 01:12 ET
Victrex Plc Raises FY26 Underlying PBT View; Appoints Interim CFO; Stock Rises 12.8%
September 09, 2026 03:28 ET
Chime To Acquire Stride Bank
September 09, 2026 01:26 ET
Autohellas S.A. Reveals Fall In H1 Profit
September 09, 2026 03:33 ET
Antin Infrastructure Partners SAS Profit Drops In H1
September 09, 2026 01:29 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Vallourec, Aramco Ink Agreement For Supply Of Oil Country Tubular Goods
September 09, 2026 01:45 ET
TENPOS HOLDINGS Co Ltd. Reveals Retreat In Q1 Profit
September 09, 2026 05:03 ET
Editors Pick
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Loading...
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。